ALNOV.PANovacyt S.A.
The schedule
- Wed18Nov
Anticipated regulatory decision for the IVDR accreditation of Novacyt's DPYD pharmacogenomics kit, a key expansion into the European oncology screening market.
- Mon28Dec
- Thu21Jan
The company's annual unaudited FY 2026 trading update, providing a first look at full-year sales and the momentum of the LightBench Discover platform.
- Wed10Mar
Evaluation of the company's capital runway, assessing the structural risk of equity dilution required to fund ongoing R&D and commercial expansion.
- Mon29Mar
- Thu22Apr
Release of the audited full-year 2026 earnings report, finalizing net income figures and providing clinical pipeline guidance for 2027.
- Mon28Jun
- Mon27Sep
Past
- Thu24Sep
Novacyt is scheduled to report its H1 2026 financial results, detailing the bottom-line impact of its £4.0M restructuring program and the Southern Cross Diagnostics acquisition.